Back to Journals » Clinical Ophthalmology » Volume 8

One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy

Authors Sakurai M, Baba T, Kitahashi M, Yokouchi H, Kubota-Taniai M, Bikbova G, Oshitari T, Yamamoto S

Received 16 September 2013

Accepted for publication 15 October 2013

Published 28 January 2014 Volume 2014:8 Pages 235—241

DOI https://doi.org/10.2147/OPTH.S54578

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Madoka Sakurai, Takayuki Baba, Masayasu Kitahashi, Hirotaka Yokouchi, Mariko Kubota-Taniai, Guzel Bikbova, Toshiyuki Oshitari, Shuichi Yamamoto

Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan

Purpose: To compare the 1-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy (RF-PDT) to intravitreal ranibizumab (IVR) alone for eyes with polypoidal choroidal vasculopathy (PCV).
Methods: We reviewed the medical records from 47 consecutive patients with PCV (47 naïve eyes). Seventeen eyes from 17 patients had one IVR treatment combined with RF-PDT followed by two additional IVR treatments (combined group), and 30 eyes from 30 patients were treated with 3 monthly IVR treatments (IVR group). All eyes had a follow-up period of at least 12 months.
Results: At 12 months, the mean logarithm of the minimal angle of resolution (logMAR) best-corrected visual acuity (BCVA) significantly improved from 0.55 to 0.38 logMAR units in the combined group (P=0.041) but did not change significantly in the IVR group (P=0.371). The central foveal thickness (CFT) was significantly thinner in both groups at 6 months (P<0.01). Additional IVR injections were required less frequently in the combined group (n=3; 17%) than in the IVR group (n=16; 53%) during the 12 month follow-up (P=0.029).
Conclusion: The IVR and RF-PDT combination led to significant BCVA improvements and required fewer additional IVR treatments for at least 12 months in eyes with PCV.

Keywords: intravitreal ranibizumab, reduced-fluence photodynamic therapy, polypoidal choroidal vasculopathy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]